Journal article · 2026 · Open access

High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice

Hirohisa Mekata, Mari YAMAMOTO, Takeshi Kawaguchi, Tamaki Okabayashi

Veterinary Microbiology, 323, 111264 · Published 23 October 2026 · DOI 10.1016/j.vetmic.2026.111264

Open full textCite this paper

In brief

“High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice” is a 2026 journal article by Hirohisa Mekata and 3 co-authors, published in Veterinary Microbiology. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at Veterinary Microbiology.

Citations
0
References
33
Authors
4

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne zoonosis caused by severe fever with thrombocytopenia syndrome virus (SFTSV) and is associated with high case-fatality rates in humans and cats. No vaccines or antiviral drugs are currently available for the prevention or treatment of feline SFTS. We hypothesized that some cats that recover from naturally acquired SFTS develop high neutralizing antibody titers and may serve as a source of convalescent serum for passive immunotherapy. We measured 80% plaque-reduction neutralization test (PRNT 80 ) titers in convalescent sera from six human SFTS survivors and 14 cats that had recovered from naturally acquired SFTS, and then evaluated the therapeutic efficacy of convalescent cat serum in SFTSV-infected, interferon receptor-deficient AG129 mice. Some SFTS-recovered cats exhibited high PRNT 80 titers. Passive administration of high-titer convalescent cat serum early after infection protected SFTSV-infected mice. A single dose given at 2 or 3 days post-infection completely protected mice, whereas treatment at 4 days post-infection resulted in 40% survival. In the repeated-dose experiment, early treatment was associated with lower blood viral RNA levels than controls at 6 dpi, and surviving mice also showed low viral RNA levels at 13 dpi. Sera from three additional SFTS-recovered cats also improved survival. Collectively, these findings indicate that some SFTS-recovered cats can develop high neutralizing antibody titers and that their sera can exert therapeutic effects in an SFTSV-infected mouse model, supporting further evaluation of passive immunotherapy as a treatment strategy for feline SFTS.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mekata, H., YAMAMOTO, M., Kawaguchi, T., & Okabayashi, T. (2026). High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice. Veterinary Microbiology, 323, 111264. https://doi.org/10.1016/j.vetmic.2026.111264

MLA 9

Mekata, Hirohisa, et al. “High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice.” Veterinary Microbiology, vol. 323, 2026, p. 111264. https://doi.org/10.1016/j.vetmic.2026.111264.

Chicago

Mekata, Hirohisa, Mari YAMAMOTO, Takeshi Kawaguchi, and Tamaki Okabayashi. 2026. “High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice.” Veterinary Microbiology 323: 111264. https://doi.org/10.1016/j.vetmic.2026.111264.

Harvard

Mekata, H. et al. (2026) ‘High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice’, Veterinary Microbiology, 323, p. 111264. doi:10.1016/j.vetmic.2026.111264.

IEEE

H. Mekata, M. YAMAMOTO, T. Kawaguchi, and T. Okabayashi, “High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice,” Veterinary Microbiology, vol. 323, p. 111264, 2026, doi: 10.1016/j.vetmic.2026.111264.

BibTeX

@article{mekata2026high,
  title     = {{High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice}},
  author    = {Mekata, Hirohisa and YAMAMOTO, Mari and Kawaguchi, Takeshi and Okabayashi, Tamaki},
  journal   = {Veterinary Microbiology},
  year      = {2026},
  volume    = {323},
  pages     = {111264},
  doi       = {10.1016/j.vetmic.2026.111264},
  url       = {https://doi.org/10.1016/j.vetmic.2026.111264}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › Viral Infections and Vectors

  • severe fever with thrombocytopenia syndrome
  • SFTSV
  • convalescent serum
  • passive immunotherapy
  • neutralizing antibodies
  • cats
  • AG129 mice
  • tick-borne zoonoses

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Mekata, H., YAMAMOTO, M., Kawaguchi, T., & Okabayashi, T. (2026). High-titer convalescent serum from cats recovered from severe fever with thrombocytopenia syndrome protects SFTSV-infected mice. Veterinary Microbiology, 323, 111264. https://doi.org/10.1016/j.vetmic.2026.111264

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Veterinary Microbiology: sign in and open the full text from this page.

Who wrote this paper?

Hirohisa Mekata, Mari YAMAMOTO, Takeshi Kawaguchi, Tamaki Okabayashi.

What is the DOI of this paper?

10.1016/j.vetmic.2026.111264, permanently at https://doi.org/10.1016/j.vetmic.2026.111264. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.